Gene therapy injection aimed at slowing ALS enters human testing
NCT ID NCT07290062
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial is testing a single injection of a gene therapy called INS1202, given into the spinal fluid, for people with ALS (Lou Gehrig's disease). The study includes 23 adults, some with a specific genetic mutation (SOD1) and some without known genetic causes. The main goal is to check safety and find the right dose, not yet to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INS1202 (gene therapy given as a single injection into the spinal fluid)
What this could lead to
If safe and effective, this could point toward a treatment that slows or stops the progression of ALS, a devastating nerve disease.
What could go wrong
This is a very early Phase 1 trial with only 23 people, so it is primarily checking safety, not whether it works. Gene therapies can have unexpected side effects, and the benefit may be small or absent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
USA001
RECRUITINGColumbia, Missouri, 65211, United States
Contact Email: •••••@•••••
-
USA002
RECRUITINGPalo Alto, California, 94304, United States
Contact Email: •••••@•••••
-
USA004
RECRUITINGLa Jolla, California, 92037, United States
Contact Email: •••••@•••••
-
USA006
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
-
USA007
RECRUITINGColumbus, Ohio, 43221, United States
Contact Email: •••••@•••••